- Home
- BNTX vs DXCM Comparison
BNTX vs DXCM Comparison
Compare BNTX & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | DXCM |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 25.9B |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BNTX | DXCM |
|---|---|---|
| Price | $95.46 | $67.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | ★ $137.40 | $86.86 |
| AVG Volume (30 Days) | 1.6M | ★ 5.1M |
| Earning Date | 11-03-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.75 |
| EPS | N/A | ★ 1.80 |
| Revenue | $3,698,814,972.00 | ★ $4,515,900,000.00 |
| Revenue This Year | $2.03 | $17.41 |
| Revenue Next Year | N/A | $12.78 |
| P/E Ratio | ★ N/A | $37.21 |
| Revenue Growth | 3.70 | ★ 14.21 |
| 52 Week Low | $81.20 | $54.11 |
| 52 Week High | $129.27 | $93.25 |
Technical Indicators
Market Signals| Indicator | BNTX | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 59.48 |
| Support Level | $91.32 | $65.56 |
| Resistance Level | $93.76 | $67.95 |
| Average True Range (ATR) | 2.09 | 1.87 |
| MACD | 0.18 | 0.10 |
| Stochastic Oscillator | 46.39 | 59.27 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.